Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Crago

Showing results (61-70 of 85) with videos related to

Pageof 9
Sort By:
Science Signaling|September 26, 2013
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targetsMartin L Miller, Evan J Molinelli, Jayasree S Nair, et al.
Oncogene|May 24, 2018
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescenceMary E Klein, Mark A Dickson, Cristina Antonescu, et al.
Oncotarget|March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibitionMarta Kovatcheva, David D Liu, Mark A Dickson, et al.
Annals of Surgical Oncology|July 16, 2021
Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical ResectionJacob E Mandel, DaeHee Kim, Hooman Yarmohammadi, et al.
Oncology|June 6, 2015
Outcomes of Systemic Therapy for Patients with Metastatic AngiosarcomaSandra P D'Angelo, Rodrigo R Munhoz, Deborah Kuk, et al.
Genes, Chromosomes & Cancer|July 15, 2015
Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysisAimee M Crago, Juliann Chmielecki, Mara Rosenberg, et al.
Sarcoma|June 18, 2016
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine LeiomyosarcomaA N Shoushtari, J Landa, D Kuk, et al.
JAMA Oncology|April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical TrialMark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Annals of Surgery|April 5, 2019
Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib ErasMichael J Cavnar, Kenneth Seier, Christina Curtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
Pageof 9

Showing results (61-70 of 85) with videos related to

Sort By:
Pageof 9
Science Signaling|September 26, 2013
Drug synergy screen and network modeling in dedifferentiated liposarcoma identifies CDK4 and IGF1R as synergistic drug targetsMartin L Miller, Evan J Molinelli, Jayasree S Nair, et al.
Oncogene|May 24, 2018
PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescenceMary E Klein, Mark A Dickson, Cristina Antonescu, et al.
Oncotarget|March 25, 2015
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibitionMarta Kovatcheva, David D Liu, Mark A Dickson, et al.
Annals of Surgical Oncology|July 16, 2021
Percutaneous Cryoablation Provides Disease Control for Extra-Abdominal Desmoid-Type Fibromatosis Comparable with Surgical ResectionJacob E Mandel, DaeHee Kim, Hooman Yarmohammadi, et al.
Oncology|June 6, 2015
Outcomes of Systemic Therapy for Patients with Metastatic AngiosarcomaSandra P D'Angelo, Rodrigo R Munhoz, Deborah Kuk, et al.
Genes, Chromosomes & Cancer|July 15, 2015
Near universal detection of alterations in CTNNB1 and Wnt pathway regulators in desmoid-type fibromatosis by whole-exome sequencing and genomic analysisAimee M Crago, Juliann Chmielecki, Mara Rosenberg, et al.
Sarcoma|June 18, 2016
Overall Survival and Response to Systemic Therapy in Metastatic Extrauterine LeiomyosarcomaA N Shoushtari, J Landa, D Kuk, et al.
JAMA Oncology|April 29, 2016
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib: A Phase 2 Clinical TrialMark A Dickson, Gary K Schwartz, Mary Louise Keohan, et al.
Annals of Surgery|April 5, 2019
Outcome of 1000 Patients With Gastrointestinal Stromal Tumor (GIST) Treated by Surgery in the Pre- and Post-imatinib ErasMichael J Cavnar, Kenneth Seier, Christina Curtin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcomaMark A Dickson, William D Tap, Mary Louise Keohan, et al.
Pageof 9